Mycobacterium abscessus

Beyond Air Publishes New Data on Nitric Oxide to Treat M. Abscessus in the Peer-Reviewed Journal Access Microbiology

Retrieved on: 
Monday, August 10, 2020
Acid-fast bacilli, Mycobacterium abscessus, Preclinical development, Organisms, Medical specialties, Branches of biology

The patient had an eight-year history of M. abscessus refractory to treatment with multiple drug combinations.

Key Points: 
  • The patient had an eight-year history of M. abscessus refractory to treatment with multiple drug combinations.
  • In vitro susceptibility tests showed a dose-dependent NO effect on M. abscessus susceptibility and significant heterogeneity in response among M. abscessus clinical isolates.
  • These data are in line with our other preclinical and clinical studies, said Steve Lisi, Chairman and Chief Executive Officer of Beyond Air.
  • Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made.

Crestone, Inc. (Boulder) Secures CFF Funding for Preclinical Development of Novel Antibiotic to Treat NTM Infections

Retrieved on: 
Monday, January 13, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Medical specialties, Infectious diseases, Bacteria, Bacterial diseases, Acid-fast bacilli, Bacteriology, Healthcare-associated infections, Nontuberculous mycobacteria, Mycobacterium abscessus, Mycobacterium, NTM, Tuberculosis

Crestone, Inc. today announced an award from the Cystic Fibrosis Foundation (CFF) for the preclinical development of its antibiotic lead series to treat nontuberculous mycobacteria (NTM) infections, focusing on M. abscessus.

Key Points: 
  • Crestone, Inc. today announced an award from the Cystic Fibrosis Foundation (CFF) for the preclinical development of its antibiotic lead series to treat nontuberculous mycobacteria (NTM) infections, focusing on M. abscessus.
  • Pulmonary NTM disease is steadily increasing in the U.S., projected to be 180,000 cases and associated medical costs of $1.7 billion.
  • Treatment of NTM infections is difficult due to antimicrobial resistance and drug-related toxicities.
  • Crestones lead candidates possess excellent in vitro potency and were identified in a medicinal chemistry campaign with SBIR funding from NIH.

Beyond Air™ Presents Data at the 2019 European Respiratory Society (ERS) International Congress in Madrid, Spain

Retrieved on: 
Tuesday, October 1, 2019
Infectious diseases, Medical specialties, Bacteria, Acid-fast bacilli, Bacterial diseases, Bacteriology, Healthcare-associated infections, Tuberculosis, Nontuberculous mycobacteria, Mycobacterium abscessus, Mycobacterium, NTM

M. abscessus is an emerging species of multidrug-resistant nontuberculous mycobacteria (NTM) with increasing prevalence in patients with underlying pulmonary disease.

Key Points: 
  • M. abscessus is an emerging species of multidrug-resistant nontuberculous mycobacteria (NTM) with increasing prevalence in patients with underlying pulmonary disease.
  • We look forward to continuing to build upon these data with intermittent NO exposure mimicking our anticipated human clinical protocols.
  • A copy of the presentation materials can be accessed on the Events section of the Beyond Air website.
  • Welcoming over 20,000 delegates every year, the annual ERS Congress is a showcase of excellence across the entire field of respiratory medicine.